患者招募_健趣网

Row	Study Title	Conditions	Interventions	Detail
322	The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)	Endometrial Cancer	Drug:Rucaparib Drug:Bevacizumab Drug:Atezolizumab	detail
323	Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence	Anatomic Stage II Breast Cancer\|Anatomic Stage IIA Breast Cancer\|Anatomic Stage IIB Breast Cancer\|Anatomic Stage III Breast Cancer\|Anatomic Stage IIIA Breast Cancer\|Anatomic Stage IIIB Breast Cancer\|Anatomic Stage IIIC Breast Cancer\|Clinical Stage II Esophageal Adenocarcinoma\|Clinical Stage II Esophageal Squamous Cell Carcinoma\|Clinical Stage II Gastric Cancer\|Clinical Stage II Gastroesophageal Junction Adenocarcinoma\|Clinical Stage IIA Esophageal Adenocarcinoma\|Clinical Stage IIA Gastric Cancer\|Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma\|Clinical Stage IIB Esophageal Adenocarcinoma\|Clinical Stage IIB Gastric Cancer\|Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma\|Clinical Stage III Esophageal Adenocarcinoma\|Clinical Stage III Esophageal Squamous Cell Carcinoma\|Clinical Stage III Gastric Cancer\|Clinical Stage III Gastroesophageal Junction Adenocarcinoma\|Distal Esophagus Squamous Cell Carcinoma\|Esophageal Carcinoma\|Estrogen Receptor Negative\|HER2/Neu Negative\|Limited Stage Small Cell Lung Carcinoma\|Malignant Solid Neoplasm\|Non-Small Cell Lung Carcinoma\|Pancreatic Adenocarcinoma\|Pathologic Stage II Esophageal Adenocarcinoma\|Pathologic Stage II Esophageal Squamous Cell Carcinoma\|Pathologic Stage II Gastric Cancer\|Pathologic Stage II Gastroesophageal Junction Adenocarcinoma\|Pathologic Stage IIA Esophageal Adenocarcinoma\|Pathologic Stage IIA Esophageal Squamous Cell Carcinoma\|Pathologic Stage IIA Gastric Cancer\|Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma\|Pathologic Stage IIB Esophageal Adenocarcinoma\|Pathologic Stage IIB Esophageal Squamous Cell Carcinoma\|Pathologic Stage IIB Gastric Cancer\|Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma\|Pathologic Stage III Esophageal Adenocarcinoma\|Pathologic Stage III Esophageal Squamous Cell Carcinoma\|Pathologic Stage III Gastric Cancer\|Pathologic Stage III Gastroesophageal Junction Adenocarcinoma\|Pathologic Stage IIIA Esophageal Adenocarcinoma\|Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma\|Pathologic Stage IIIA Gastric Cancer\|Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma\|Pathologic Stage IIIB Esophageal Adenocarcinoma\|Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma\|Pathologic Stage IIIB Gastric Cancer\|Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma\|Pathologic Stage IIIC Gastric Cancer\|Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma\|Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma\|Postneoadjuvant Therapy Stage II Gastric Cancer\|Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma\|Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma\|Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma\|Postneoadjuvant Therapy Stage III Gastric Cancer\|Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma\|Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma\|Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma\|Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma\|Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma\|Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma\|Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma\|Progesterone Receptor Negative\|Prognostic Stage II Breast Cancer\|Prognostic Stage IIA Breast Cancer\|Prognostic Stage IIB Breast Cancer\|Prognostic Stage III Breast Cancer\|Prognostic Stage IIIA Breast Cancer\|Prognostic Stage IIIB Breast Cancer\|Prognostic Stage IIIC Breast Cancer\|Stage I Pancreatic Cancer\|Stage IA Pancreatic Cancer\|Stage IB Pancreatic Cancer\|Stage II Lung Cancer\|Stage II Pancreatic Cancer\|Stage IIA Lung Cancer\|Stage IIA Pancreatic Cancer\|Stage IIB Lung Cancer\|Stage IIB Pancreatic Cancer\|Stage III Lung Cancer\|Stage IIIA Lung Cancer\|Stage IIIB Lung Cancer\|Stage IIIC Lung Cancer\|Triple-Negative Breast Carcinoma	Drug:Ifetroban Sodium Other:Placebo	detail
324	Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage II/IIIa NSCLC	Potentially Resectable Stage II/IIIa NSCLC	Drug:durvalumab	detail
325	Health Education Delivery Methods for a Low Fermentable Carbohydrate Diet in Patients With Functional Bowel Disorders	Irritable Bowel Syndrome\|Functional Diarrhea\|Functional Bowel Disorder	Other:Health education delivery methods	detail
326	EndoRotor DEN (Direct Endoscopic Necrosectomy)Trial	Acute Pancreatic Necrosis\|Acute Pancreatitis	Device:EndoRotor Therapy	detail
327	Long Term Safety Study of PRALUENT	Heterozygous Familial Hypercholesterolemia\|Non-familial Hypercholesterolemia	Drug:Praluent	detail
328	A Pilot Study of the Effect of Individualized Clinical Management Among Parent/Child Dyads on Continuity of Care and Interaction	Child Psychiatry, Conitnuity/Disconitnuity, Psychodynamic Therapy	:	detail
330	Effect of IL-4RαR576 Polymorphism on Response to Dupilumab in Children With Asthma	Asthma	Drug:Dupilumab	detail
331	Predicting Diabetic Retinopathy From Risk Factor Data and Digital Retinal Images	Diabetic Retinopathy\|Diabetic Macular Edema	Other:In-Person Eye Examination	detail
332	Brain Excitability and Connectivity in Sensory-motor Pathways in ALS	Amyotrophic Lateral Sclerosis	Device:functional MRI Device:structural MRI Device:EEG/MEG	detail

上一页 26 27 28 29 30 31 32 下一页为您找到500条信息